Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) Director Michael J.M. Hitchcock acquired 10,000 shares of Biomea Fusion stock in a transaction dated Monday, September 30th. The stock was purchased at an average cost of $10.06 per share, with a total value of $100,600.00. Following the completion of the purchase, the director now owns 15,000 shares of the company’s stock, valued at $150,900. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Biomea Fusion Stock Down 5.9 %
Biomea Fusion stock traded down $0.60 during mid-day trading on Tuesday, reaching $9.50. 902,217 shares of the company’s stock traded hands, compared to its average volume of 1,052,377. Biomea Fusion, Inc. has a 12-month low of $3.61 and a 12-month high of $22.74. The stock has a 50 day moving average of $6.99 and a two-hundred day moving average of $8.85. The company has a market cap of $341.48 million, a price-to-earnings ratio of -2.61 and a beta of -0.47.
Biomea Fusion (NASDAQ:BMEA – Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported ($1.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.03). As a group, sell-side analysts forecast that Biomea Fusion, Inc. will post -4.09 earnings per share for the current year.
Institutional Investors Weigh In On Biomea Fusion
Analysts Set New Price Targets
BMEA has been the subject of a number of analyst reports. RODMAN&RENSHAW upgraded Biomea Fusion to a “strong-buy” rating in a research note on Thursday, September 26th. Citigroup decreased their target price on Biomea Fusion from $45.00 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Scotiabank boosted their price target on Biomea Fusion from $21.00 to $41.00 and gave the stock a “sector outperform” rating in a report on Friday. Piper Sandler cut their price objective on shares of Biomea Fusion from $45.00 to $10.00 and set an “overweight” rating for the company in a report on Friday, June 7th. Finally, Barclays lifted their price objective on shares of Biomea Fusion from $5.00 to $9.00 and gave the company an “equal weight” rating in a research report on Friday. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Biomea Fusion currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.
View Our Latest Stock Analysis on Biomea Fusion
Biomea Fusion Company Profile
Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.
See Also
- Five stocks we like better than Biomea Fusion
- Industrial Products Stocks Investing
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Are Dividend Champions? How to Invest in the Champions
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What Do S&P 500 Stocks Tell Investors About the Market?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.